Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 273

1.

Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials.

Pun PH, Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT, Buxton AE, Moss AJ, Lee KL, Steinman R, Dorian P, Hallstrom A, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Hess PL, Inoue LY, Sanders GD.

Am J Kidney Dis. 2014 Jul;64(1):32-9. doi: 10.1053/j.ajkd.2013.12.009.

2.

Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.

Health Quality Ontario..

Ont Health Technol Assess Ser. 2005;5(14):1-74.

3.

Implantable cardioverter-defibrillators in patients with CKD: a propensity-matched mortality analysis.

Nakhoul GN, Schold JD, Arrigain S, Harb SC, Jolly S, Wilkoff BL, Nally JV Jr, Navaneethan SD.

Clin J Am Soc Nephrol. 2015 Jul 7;10(7):1119-27. doi: 10.2215/CJN.11121114.

4.

Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials.

Hess PL, Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT, Buxton A, Cappato R, Dorian P, Hallstrom A, Kadish AH, Kudenchuk PJ, Lee KL, Mark DB, Moss AJ, Steinman R, Inoue LY, Sanders G.

Circ Cardiovasc Qual Outcomes. 2015 Mar;8(2):179-86. doi: 10.1161/CIRCOUTCOMES.114.001306.

5.

Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials.

Steinberg BA, Al-Khatib SM, Edwards R, Han J, Bardy GH, Bigger JT, Buxton AE, Moss AJ, Lee KL, Steinman R, Dorian P, Hallstrom A, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Inoue LY, Sanders GD.

JACC Heart Fail. 2014 Dec;2(6):623-9. doi: 10.1016/j.jchf.2014.06.007.

6.

Survival after primary prevention implantable cardioverter-defibrillator placement among patients with chronic kidney disease.

Hess PL, Hellkamp AS, Peterson ED, Sanders GD, Al-Khalidi HR, Curtis LH, Hammill BG, Pun PH, Curtis JP, Anstrom KJ, Hammill SC, Al-Khatib SM.

Circ Arrhythm Electrophysiol. 2014 Oct;7(5):793-9. doi: 10.1161/CIRCEP.114.001455.

7.

New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II.

Klein H, Auricchio A, Reek S, Geller C.

Am J Cardiol. 1999 Mar 11;83(5B):91D-97D. Review.

PMID:
10089848
8.

Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials.

Hess PL, Laird A, Edwards R, Bardy GH, Bigger JT, Buxton AE, Moss AJ, Lee KL, Hall WJ, Steinman R, Dorian P, Hallstrom A, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Al-Khatib SM, Piccini JP, Inoue LY, Sanders GD.

Heart Rhythm. 2013 Jun;10(6):828-35. doi: 10.1016/j.hrthm.2013.02.011.

9.

Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials.

Al-Khatib SM, Hellkamp A, Bardy GH, Hammill S, Hall WJ, Mark DB, Anstrom KJ, Curtis J, Al-Khalidi H, Curtis LH, Heidenreich P, Peterson ED, Sanders G, Clapp-Channing N, Lee KL, Moss AJ.

JAMA. 2013 Jan 2;309(1):55-62. doi: 10.1001/jama.2012.157182.

10.

Predictors of mortality in patients with chronic kidney disease and an implantable defibrillator: an EPGEN substudy.

Williams ES, Shah SH, Piccini JP, Sun AY, Koontz JI, Al-Khatib SM, Hranitzky PM.

Europace. 2011 Dec;13(12):1717-22. doi: 10.1093/europace/eur253.

11.
14.

Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.

Lelakowski J, Piekarz J, Rydlewska A, Majewski J, Senderek T, Ząbek A, Małecka B.

Kardiol Pol. 2012;70(11):1099-110.

15.
16.

Defibrillator implantations for primary prevention in the United States: Inappropriate care or inadequate documentation: Insights from the National Cardiovascular Data ICD Registry.

Kaiser DW, Tsai V, Heidenreich PA, Goldstein MK, Wang Y, Curtis J, Turakhia MP; National Cardiovascular Data Registry..

Heart Rhythm. 2015 Oct;12(10):2086-93. doi: 10.1016/j.hrthm.2015.05.010.

17.

Kidney dysfunction and deterioration of ejection fraction pose independent risk factors for mortality in implantable cardioverter-defibrillator recipients for primary prevention.

Kreuz J, Horlbeck F, Schrickel J, Linhart M, Fimmers R, Mellert F, Nickenig G, Schwab JO.

Clin Cardiol. 2012 Sep;35(9):575-9. doi: 10.1002/clc.22018.

18.

Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials.

Ghanbari H, Dalloul G, Hasan R, Daccarett M, Saba S, David S, Machado C.

Arch Intern Med. 2009 Sep 14;169(16):1500-6. doi: 10.1001/archinternmed.2009.255.

PMID:
19752408
19.

Outcomes in African Americans undergoing cardioverter-defibrillator implantation for primary prevention of sudden cardiac death: findings from the Prospective Observational Study of Implantable Cardioverter-Defibrillators (PROSE-ICD).

Zhang Y, Kennedy R, Blasco-Colmenares E, Butcher B, Norgard S, Eldadah Z, Dickfeld T, Ellenbogen KA, Marine JE, Guallar E, Tomaselli GF, Cheng A.

Heart Rhythm. 2014 Aug;11(8):1377-83. doi: 10.1016/j.hrthm.2014.04.039.

20.

Prevention of sudden cardiac death in patients with chronic kidney disease: risk and benefits of the implantable cardioverter defibrillator.

Hoffmeister JM, Estes NA 3rd, Garlitski AC.

J Interv Card Electrophysiol. 2012 Nov;35(2):227-34. doi: 10.1007/s10840-012-9711-4. Review.

PMID:
22956011
Items per page

Supplemental Content

Support Center